Millions of Medicare beneficiaries who rely on prescription drugs for cancer, diabetes, and asthma will see lower costs after the federal government finalized negotiated prices on 15 widely used medications. The Centers for Medicare and Medicaid Services projects the deals will cut net spending by roughly 44 percent, saving an estimated $12 billion compared with 2024 levels. The second round of price negotiations also sets up a broader fight over how insurers and pharmacy benefit managers structure their formularies in response.
How $12 billion in drug savings reshapes Part D coverage
The 15 drugs targeted in this second negotiation cycle rank among Medicare’s highest-cost Part D products. CMS released the maximum fair prices on Nov. 25, 2025, locking in discounts that apply once the prices take effect. The medications treat chronic conditions that affect tens of millions of enrollees, and the projected $12 billion reduction represents a significant share of total Part D spending on these products.
Yet a lower list price does not automatically translate into lower copays at the pharmacy counter. Individual Part D plan designs, tiering decisions, and cost-sharing formulas all sit between the negotiated price and what a patient actually pays. That gap raises a practical question: will plan sponsors pass the savings through, or will they use the newly discounted drugs as leverage to steer patients toward competing therapies that generate higher rebates?
The structure of the negotiation program creates an incentive for exactly that kind of shift. When a brand-name drug receives a Maximum Fair Price, its net cost to the plan drops. But therapeutically similar drugs in the same class that were not selected for negotiation may still carry large manufacturer rebates. Plan sponsors could respond by favoring those non-negotiated competitors on preferred formulary tiers, effectively using the negotiation program’s existence to extract better deals across an entire drug class. Within 24 months of implementation, this dynamic could produce a measurable increase in formulary placement for non-negotiated competitor drugs, reshaping prescribing patterns in cancer, diabetes, and asthma treatment well beyond the 15 drugs directly affected.
CMS data and GAO review anchor the savings estimate
The 44 percent savings figure and $12 billion estimate both come directly from CMS, which published the negotiated prices and supporting files on its program page. The agency calculated the reduction against 2024 net spending on the same 15 products, providing a clear baseline for the comparison. CMS used claims data, utilization trends, and current rebate levels to model what plans would have paid absent negotiation, then contrasted that scenario with projected spending under the new prices.
Separately, the U.S. Government Accountability Office has documented the program’s final guidance as a formal rule subject to congressional review, adding an independent layer of legal verification to the process CMS followed. That review does not second-guess the economic assumptions behind the $12 billion estimate, but it does confirm that the agency adhered to statutory requirements in selecting drugs, defining negotiation timelines, and publishing the resulting prices.
The program is already expanding. CMS has selected another 15 drugs for a third negotiation cycle, with deals set to take effect in 2028. According to a recent CMS announcement, that round will include Part B drugs for the first time, extending price negotiations to physician-administered treatments such as infusions and injections that were previously outside the program’s reach. The expansion means the financial pressure on drugmakers will grow, and so will the potential for formulary disruption across therapeutic classes.
Unanswered questions about out-of-pocket savings
What remains uncertain is how much of the negotiated savings will show up as lower out-of-pocket costs for individual beneficiaries. Part D plans retain broad discretion over formulary design, including which tier a drug occupies, whether it is subject to prior authorization or step therapy, and how coinsurance rates are set for each tier. Plans could respond to the new prices by moving negotiated drugs to more favorable tiers, trimming coinsurance percentages, or waiving deductibles for certain chronic conditions. They could also keep negotiated drugs on higher tiers while using lower net costs to improve their own margins or reduce overall premiums.
Another open question is how the new prices will interact with recent changes to the Part D benefit structure, including a hard cap on annual out-of-pocket spending. Lower negotiated prices reduce the total amount of spending that counts toward that cap, potentially delaying the point at which beneficiaries hit the limit and see their cost sharing fall sharply. For high-cost cancer therapies in particular, the balance between lower per-prescription prices and the timing of catastrophic coverage could determine whether patients feel meaningful relief.
Clinicians and patient advocates are also watching for unintended clinical consequences. If plans steer patients toward non-negotiated competitors that offer higher rebates, some enrollees may be pushed to switch therapies even when they are stable on a negotiated drug. That could introduce new risks around adherence, side effects, and disease control, especially for complex regimens in oncology and advanced diabetes care. CMS has authority to monitor access and could intervene if patterns of formulary design appear to undermine the intent of the negotiation program, but how aggressively it will use that oversight remains to be seen.
For now, the finalized prices mark a turning point in how Medicare pays for some of its most expensive drugs. The projected $12 billion in savings underscores the fiscal stakes, while the looming expansion into Part B signals that the program will reach deeper into the pharmaceutical market. Whether seniors ultimately experience those savings at the pharmacy counter will depend on a series of decisions by insurers, pharmacy benefit managers, and regulators that will play out over the next several plan years.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
